Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00296725 · ClinicalTrials.gov registry record · Phase 1
Dichotic Listening as a Predictor of Medication Response in Depression
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00296725 is a Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 25 participants.
The verdict
NCT00296725, a Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Depressed patients will have hearing tests and then be treated with up to three treatments (i.e., Fluoxetine, Imipramine) until remitted, to see whether test results predict specific outcomes.
Interventions
- DRUG Imipramine
- DRUG Fluoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1994-04 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00296725
The ClinicalTrials.gov registry entry for NCT00296725 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Imipramine is the first listed.
NCT00296725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00296725 about?
NCT00296725 is a clinical study titled "Dichotic Listening as a Predictor of Medication Response in Depression". Depressed patients will have hearing tests and then be treated with up to three treatments (i.e., Fluoxetine, Imipramine) until remitted, to see whether test results predict specific outcomes.
What is the current status of trial NCT00296725?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 1994-04. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00296725?
The interventions under investigation include: Imipramine (DRUG), Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00296725?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.